文献速递产科母胎医学

抗血小板药物与自发性早产预防:系统综述与Meta分析

Antiplatelet Agents and the Prevention of Spontaneous Preterm Birth: A Systematic Review and Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2017-01-01

本研究基于个体参与者数据Meta分析,纳入17项试验共28797名女性,评估抗血小板药物(低剂量阿司匹林-双嘧达莫)对比安慰剂或无治疗对自发性早产的影响。结果显示,抗血小板治疗组自发性早产<37周(RR 0.93,95%CI 0.86-0.996)和<34周(RR 0.86,95%CI 0.76-0.99)风险降低;有既往妊娠史的女性<37周自发性早产RR为0.83(95%CI 0.73-0.95),首次妊娠女性为0.98(95%CI 0.89-1.09)。结论认为抗血小板药物可减少有子痫前期风险孕妇的自发性早产。

要点

  • 抗血小板药物降低有子痫前期风险孕妇<37周自发性早产风险(RR 0.93,95%CI 0.86-0.996)。
  • 抗血小板药物降低<34周自发性早产风险(RR 0.86,95%CI 0.76-0.99)。
  • 有既往妊娠史女性<37周自发性早产RR 0.83(95%CI 0.73-0.95),首次妊娠女性RR 0.98(95%CI 0.89-1.09)。

核心结论

  • 抗血小板药物可减少有子痫前期风险的孕妇发生自发性早产。

研究设计与样本

  • 本研究为基于个体参与者数据的Meta分析,数据来源于评估抗血小板药物预防子痫前期的Perinatal Antiplatelet Review of International Studies Individual Participant Data Meta分析。
  • 该Meta分析纳入31项将女性随机分配至低剂量阿司匹林-双嘧达莫或安慰剂-无治疗作为子痫前期一级预防策略的研究。
  • 当前分析纳入17项提供分娩类型(自发性与指征性分娩)数据的试验,共28797名女性。

主要发现

  • 分配至抗血小板治疗的女性与安慰剂或无治疗相比,<37周自发性早产风险较低(RR 0.93,95%CI 0.86-0.996)。
  • 抗血小板治疗组<34周自发性早产风险较低(RR 0.86,95%CI 0.76-0.99)。
  • 有既往妊娠史的女性<37周自发性早产RR为0.83(95%CI 0.73-0.95),首次妊娠女性RR为0.98(95%CI 0.89-1.09)。
  • 在所有其他预设亚组中治疗效果稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Spontaneous preterm birth is an important cause of neonatal mortality and morbidity. An increasing body of evidence suggests that uteroplacental ischemia plays an important role in the etiology of spontaneous preterm birth. We aimed to study whether antiplatelet agents reduce the risk of spontaneous preterm birth. DATA SOURCES: We included data from an individual participant data meta-analysis of studies that had evaluated the effect of antiplatelet agents to reduce preeclampsia (Perinatal Antiplatelet Review of International Studies Individual Participant Data). METHODS OF STUDY SELECTION: The meta-analysis included 31 studies that randomized women to low-dose aspirin-dipyridamole or placebo-no treatment as a primary preventive strategy for preeclampsia. For the current study we analyzed data from 17 trials (28,797 women) that supplied data on type of delivery (spontaneous compared with indicated birth). TABULATION, INTEGRATION, AND RESULTS: Primary endpoints were spontaneous preterm birth at less than 37 weeks, less than 34 weeks, and less than 28 weeks of gestation. We analyzed outcomes for each trial separately using χ statistics and combined in an individual participant data meta-analysis using a binary logistic regression model. Women assigned to antiplatelet treatment compared with placebo or no treatment had a lower risk of spontaneous preterm birth at less than 37 weeks (relative risk [RR] 0.93, 95% confidence interval [CI] 0.86-0.996) and less than 34 weeks of gestation (RR 0.86, 95% CI 0.76-0.99). The RR of having a spontaneous preterm birth at less than 37 weeks of gestation was 0.83 (95% CI 0.73-0.95) for women who have had a previous pregnancy and 0.98 (95% CI 0.89-1.09) for women in their first pregnancy. The treatment effect was stable in all other prespecified subgroups. CONCLUSION: Antiplatelet agents reduce spontaneous preterm birth in pregnant women at risk for preeclampsia.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. van Vliet EOG, Askie LA, Mol BWJ, et al. Antiplatelet Agents and the Prevention of Spontaneous Preterm Birth: A Systematic Review and Meta-analysis. Obstet Gynecol. 2017. PMID: 28079785. doi:10.1097/AOG.0000000000001848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。